glp-1 mash Resmetirom and agonists for MASH: complementary rather than exclusive FDA Approves Wegovy® as First
Description
Reported adverse effects include gastroparesis, intestinal obstructions, and pancreatitis, concerns that have been substantiated by recent studies and warnings from the Food and Drug Administration (FDA)
El mejor endocrinlogo para el cuidado de la obesidad y la diabetes.
GLP-1 receptor agonists improve insulin sensitivity and promote weight loss in addition to anti-inflammatory properties independent of weight loss, Tah said
Referral to endocrinology, nutrition specialists, or mental health professionals may be appropriate for complex cases
